课题基金 / 基金详情

Mechanisms of luminal protein targeting in kidney and hepatic epithelial cells

Mechanisms of luminal protein targeting in kidney and hepatic epithelial cells
管腔蛋白靶向肾和肝上皮细胞的机制
批准号:
8505478
负责人:
ANNE MUESCH
金额:
$48.18万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-07-01 至 2016-06-30

项目摘要

项目成果

ANNE MUESCH的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):肾和肝上皮细胞中管腔蛋白靶向的机制柱状上皮(例如肾、肠)和肝细胞体现了非复层上皮细胞的两种主要组织表型。它们在形态学上的不同之处在于柱状上皮在相对的两极建立其顶端域(AP)和基底外侧域(BL),而肝细胞在其BL域中间建立其AP域、胆汁杯(BC)。它们在如何建立和维持表面结构域方面也有很大的不同。柱状上皮细胞主要将其质膜(PM)蛋白从反式高尔基体网络(TGN)靶向AP结构域,而肝细胞则将AP和BL PM蛋白从TGN靶向BL表面,在BL表面,AP蛋白通过转胞吞作用被分选为BC。尽管在了解柱状细胞(特别是肾上皮细胞系MDCK)的运输路线、分选室和靶向机制方面取得了重要进展,但对肝细胞的运输路线、分选室和机制仍然知之甚少。这在很大程度上是由于肝细胞系不适合使用MDCK细胞中使用的基于经典生物素的靶向测定进行运输研究,并且明显更难以检测。我们提出了创新的实验方法,以确定贩运行程,亚细胞区室和分子机制参与模型AP PM蛋白在肝WIFB细胞中的贩运,与MDCK细胞相比。我们的假设是:(i)新的成像技术和(ii)对AP蛋白的胞吐后命运的分析提供了足够的分辨率来理解肝细胞和柱状细胞的不同分选和运输策略,以及(iii)丝氨酸/苏氨酸激酶Par 1b充当直接途径和胞吞途径之间的分子开关。我们提出了以下具体目的:目的1:定量评估模型顶端PM蛋白在WIFB和MDCK细胞中的载体和转胞吞递送的程度。目的2:比较确定AP和BL标记在WIFB和MDCK细胞中的胞吐分选位点。目的3:鉴定AP PM蛋白在WIFB和MDCK细胞中退出TGN的机制。通过我们的新方法,我们将为一个期待已久的蛋白质靶向肝细胞与柱状细胞的比较分子模型建立框架。这是一个高度优先的上皮极性问题,超过25年来一直没有答案。
英文摘要
DESCRIPTION (provided by applicant): Mechanisms of luminal protein targeting in kidney and hepatic epithelial cells Columnar epithelia (e.g. kidney, intestine) and hepatocytes embody the two major organizational phenotypes of non-stratified epithelial cells. They differ morphologically in that columnar epithelia establish their apical domain (AP) and basolateral domains (BL) at opposing poles whereas hepatocytes establish their AP domain, the bile caliculi (BC) in the midst of their BL domains. They also differ drastically in how they establish and maintain their surface domains. Whereas columnar epithelia target their plasma membrane (PM) proteins predominantly from the trans Golgi network (TGN) to the AP domain, hepatocytes target both AP and BL PM proteins from the TGN to the BL surface, from where AP proteins are sorted to BC by transcytosis. Although important progress has been made in understanding the trafficking routes, sorting compartments, and targeting mechanisms of columnar cells, particularly the kidney epithelial cell line MDCK, the trafficking routes, and sorting compartments and mechanisms of hepatocytes remain poorly understood. This is in large part due to the fact that hepatic cell lines are not amenable to trafficking studies with the classical biotin based targeting assays utilized in MDCK cells and are distinctly more difficult to transfect. We propose innovative experimental approaches to identify the trafficking itinerary, subcellular compartments and molecular machinery involved in the trafficking of model AP PM proteins in hepatic WIFB cells, comparatively with MDCK cells. Our hypotheses are: (i) novel imaging technologies and (ii) analysis of the post-exocytic fate of AP proteins provide enough resolution to understand the different sorting and trafficking strategies of hepatocytes and columnar cells and (iii) the serine/threonine kinase Par1b acts as a molecular switch between the direct and transcytotic pathways. We propose the following Specific Aims: Aim 1: To quantitatively assess the extent of vectorial and transcytotic delivery of model apical PM proteins in WIFB and MDCK cells. Aim 2: To define comparatively the site of exocytic sorting of AP and BL markers in WIFB and MDCK cells. Aim 3: To identify the machinery used by AP PM proteins to exit the TGN in WIFB and MDCK cells. With our novel approaches we will set the framework for a long overdue comparative molecular model of protein targeting in hepatic versus columnar cells. This is a question of high priority for epithelial polarity that has remained unanswered for more than 25 years.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cell-cell adhesion-mediated signaling determines epithelial polarization in the liver
Cell-cell adhesion-mediated signaling determines epithelial polarization in the liver
Cell-cell adhesion-mediated signaling determines epithelial polarization in the liver
Par1-substrates responsible for CagA-mediated pathogenesis of Helicobacter pylori
海外基金